Incorporated in Delaware in late 2008, Cleveland-based Akrotome Imaging develops fluorescent molecular probes that help surgeons see cancer and its margins during resection. Its patented FIRE platform uses quenched probes that activate when they encounter tumor-associated enzymes, with the flexibility to be applied in the operating room and used alongside a near-infrared imaging system. The company’s current team has been in place since 2012 and is translating the technology toward breast and non-melanoma skin cancer applications.
Akrotome Conflict of Interest Policy Applicable to a Subaward Issued Under a Public Health Services Prime Award
compliance_program